New screening approach identifies small proteins unique to melanoma cells, researcher says

June 25, 2013

Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein fragments unique to melanoma cancer cells. These fragments can be used as targets for tumor-infiltrating lymphocytes that have been shown to reduce cancerous lesions.

The new approach is outlined in an article published online by Nature Medicine in May.

A previous phase 2 clinical trial showed substantial regression of metastatic lesions in up to 70 percent of melanoma patients who were treated with self-donated tumor-infiltrating lymphocytes.

"The trial, which involved the adaptive transfer of a patient's own immune cells, showed a complete lasting at least five years in nearly 40 percent of the patients," Teer said. "To better understand how this works, researchers needed to identify tumor-infiltrating lymphocytes. We developed a new method to help do that more quickly."

Tumor-infiltrating lymphocytes are that have left the bloodstream and migrated into a tumor. When numerous tumor-infiltrating lymphocytes are present, it suggests an immune response against the tumor. Research into quantifying the tumor-infiltrating lymphocytes and relating those numbers to and outcomes has been carried out across many types of cancer.

According to Teer, a better understanding of how tumor-infiltrating lymphocytes induce cancer cell regression should increase the effectiveness of patient-donated cell therapy and also potentially reveal novel mechanisms of tumor growth. The technique uses next-generation DNA sequencing technologies to identify the changes that lead to the unique protein fragments.

"Our new technique allowed us to more quickly and easily identify mutated gene antigens recognized by T-cells in the immune system," explained Teer. "Work such as this was previously done by generating and laboriously screening DNA libraries from tumors. The same screening technique may be applicable for identifying mutated antigens in a variety of tumor types."

Explore further: Modified immune cells seek and destroy melanoma

Related Stories

Modified immune cells seek and destroy melanoma

June 24, 2013
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of ...

Researchers study 'ACT TIL' approach to treating metastatic melanoma

October 17, 2012
Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes ...

Targeted stimulation of immune pathway may help body fight back against liver cancer

June 5, 2013
Though it originates from the body's own cells, a tumor is as much of a hostile invader as any virus or bacterium. If the immune system is sufficiently sensitized, it can mount a counterattack just as it might fight an infection. ...

Japanese team creates cancer-specific killer T cells from induced pluripotent stem cells

January 3, 2013
Researchers from the RIKEN Research Centre for Allergy and Immunology in Japan report today that they have succeeded for the first time in creating cancer-specific, immune system cells called killer T lymphocytes, from induced ...

Your immune system: On surveillance in the war against cancer

May 9, 2013
Predicting outcomes for cancer patients based on tumor-immune system interactions is an emerging clinical approach, and new research from Wake Forest Baptist Medical Center is advancing the field when it comes to the most ...

Engineered T cells kill tumors but spare normal tissue in an animal model

April 7, 2013
The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs. Tumor antigens, unique proteins on the surface of a tumor, are potential targets for a normal ...

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.